Skip to content
value.today
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc.

NERV
$167 Mmarket cap on Sep 30, 2026+271.0% since Jan 2024
Compare
World rank
#16,928
Revenue
—
For year ending December-2025
Net income
$-293 M
SEC filing
Employees
7
As of December 31, 2025
SEC filing

Minerva Neurosciences, Inc. in brief

Minerva Neurosciences, Inc. is a listed company in the Biotechnology industry, based in Burlington, Massachusetts, USA. Its market value was $167 M on 30 September 2026, which makes it the 16,928th largest listed company in the world and the 3,258th largest in the USA on this site. It employs about 7 people and Remy Luthringer is its chief executive. Its shares trade under the symbol NERV (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Minerva Neurosciences, Inc.

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system diseases.

Our lead product candidate, roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. In August 2022, we submitted a New Drug Application with the FDA for roluperidone for the treatment of negative symptoms in schizophrenia. On February 26, 2024, the FDA issued a Complete Response Letter regarding our NDA for roluperidone. Subsequent to the CRL, we have had multiple interactions with the FDA to confirm the design of an additional Phase 3 confirmatory clinical trial to address the deficiencies cited in the CRL and resubmit the NDA.

From the company's annual report filed with the US SEC: read the report

Minerva Neurosciences, Inc. timeline

2 events, 2014
  1. 2014
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 1 July 2014; shares registered for exchange trading on 23 June 2014.

Events of Minerva Neurosciences, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$75 M$150 M$224 M$299 M2020202120222023202420252026

World rank over time

▼ down 2,770 places since 2020
2020-01-01: #14244#14,24420202021-01-01: #18180#18,18020212022-01-07: #27415#27,41520222022-12-25: #30780#30,78020222024-01-05: #25406#25,40620242026-03-08: #8572#8,57220262026-08-01: #15138#15,13820262026-09-30: #17014#17,0142026

Rank in USA: #2,958 (Jan 2020) · #3,688 (Jan 2021) · #5,071 (Jan 2022) · #5,472 (Dec 2022) · #4,120 (Jan 2024) · #1,585 (Mar 2026) · #3,051 (Aug 2026) · #3,235 (Sep 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
-14.8%
Net margin
—
Operating margin
—
Return on equity
—
Liabilities / assets
238.6%
R&D / revenue
53.5%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-50M—FY18Fiscal year ending Dec 2019: revenue —, net income $-72M—FY19Fiscal year ending Dec 2020: revenue $41M, net income $2M$41MFY20Fiscal year ending Dec 2021: revenue —, net income $-50M—FY21Fiscal year ending Dec 2022: revenue —, net income $-32M—FY22Fiscal year ending Dec 2023: revenue —, net income $-30M—FY23Fiscal year ending Dec 2024: revenue —, net income $1M—FY24Fiscal year ending Dec 2025: revenue —, net income $-293M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-15M$-293M—
Dec 2024——$-22M$1M—
Dec 2023——$-23M$-30M—
Dec 2022——$-25M$-32M—
Dec 2021——$-45M$-50M—
Dec 2020$41M—$2M$2M4.7%
Dec 2019——$-76M$-72M—
Dec 2018——$-52M$-50M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-14M——$-34.67—
Dec 2024$-20M——$0.19—
Dec 2023$-15M——$-4.61—
Dec 2022$-25M$0M$-25M$-6.01—
Dec 2021$-25M——$-9.35—
Dec 2020$-34M——$0.05—
Dec 2019$-43M——$-1.85—
Dec 2018$-42M——$-1.29—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-4M—Dec ’24Three months to Mar 2025: revenue —, net income $-4M—Mar ’25Three months to Jun 2025: revenue —, net income $-3M—Jun ’25Three months to Sep 2025: revenue —, net income $-3M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-284M—Dec ’25Three months to Mar 2026: revenue —, net income $-125M—Mar ’26Three months to Jun 2026: revenue —, net income $17M—Jun ’26Three months to Sep 2026: revenue —, net income $101M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $101M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Minerva Neurosciences, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-15 M
Net income
$-293 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$98 M
Total liabilities
$234 M
Total equity
$-141 M

As of December-2025

Top 65 institutional investors in Minerva Neurosciences, Inc.#

As of Sep 30, 2026
65 institutions held 43.2 M shares (about 86.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 63.1%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Minerva Neurosciences, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Federated Hermes, Inc.4,670,4260 (0.00%)9.37%$16 MNov 12, 2026
2Janus Henderson Group Ltd.4,481,877—8.99%$15 MNov 16, 2026
3Vivo Capital, LLC4,322,7470 (0.00%)8.67%$14 MNov 13, 2026
4Balyasny Asset Management L.P.4,257,0000 (0.00%)8.54%$14 MNov 16, 2026
5Logos Global Management LP3,288,7770 (0.00%)6.60%$11 MNov 16, 2026
6BlackRock, Inc.2,451,359+210,781 (+9.41%)4.92%$8 MNov 13, 2026
7Farallon Capital Management, L.L.C.2,365,0000 (0.00%)4.75%$8 MNov 16, 2026
8Foresite Capital Management VI LLC1,985,5840 (0.00%)3.98%$7 MNov 16, 2026
9Vanguard Capital Management LLC1,950,629+57,822 (+3.05%)3.91%$7 MNov 13, 2026
10Ally Bridge Group (NY) LLC1,655,500-520,302 (-23.91%)3.32%$6 MNov 16, 2026
11Spruce Street Capital LP1,655,5000 (0.00%)3.32%$6 MNov 13, 2026
12Adage Capital Partners GP, L.L.C.1,419,0000 (0.00%)2.85%$5 MNov 16, 2026
13Trails Edge Capital Partners, LP1,419,0000 (0.00%)2.85%$5 MNov 16, 2026
14Millennium Management LLC1,264,334+730,732 (+136.94%)2.54%$4 MNov 16, 2026
15Seven Fleet Capital Management LP1,001,3730 (0.00%)2.01%$3 MNov 16, 2026
16Geode Capital Management, LLC977,069+2,833 (+0.29%)1.96%$3 MNov 6, 2026
17DV Equities, LLC754,3970 (0.00%)1.51%$3 MNov 16, 2026
18Acuta Capital Partners, LLC729,500+20,000 (+2.82%)1.46%$2 MNov 16, 2026
19State Street Corp609,735+184,820 (+43.50%)1.22%$2 MNov 12, 2026
20Northern Trust Corp296,243+4,126 (+1.41%)0.59%$1 MNov 16, 2026
21Vanguard Fiduciary Trust Co291,019-11,585 (-3.83%)0.58%$1 MNov 13, 2026
22Vanguard Portfolio Management LLC248,054+13,300 (+5.67%)0.50%$1 MNov 13, 2026
23Goldman Sachs Group Inc172,461+28,507 (+19.80%)0.35%$1 MNov 16, 2026
24UBS Group AG148,714+106,506 (+252.34%)0.30%$0 MNov 10, 2026
25Charles Schwab Investment Management Inc93,218-20,407 (-17.96%)0.19%$0 MNov 16, 2026
Show all 65: investors 26 to 65
Institutional investors 26 to 65 in Minerva Neurosciences, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Bank of New York Mellon Corp75,5800 (0.00%)0.15%$0 MNov 5, 2026
27Nuveen, LLC51,322+5,844 (+12.85%)0.10%$0 MNov 10, 2026
28Invesco Ltd.44,068+4,379 (+11.03%)0.09%$0 MNov 12, 2026
29Rhumbline Advisers43,101+13,234 (+44.31%)0.09%$0 MNov 10, 2026
30Apella Capital, LLC42,2500 (0.00%)0.08%$0 MOct 8, 2026
31Renaissance Technologies LLC42,000-31,300 (-42.70%)0.08%$0 MNov 12, 2026
32Bank Of America Corp /de/33,620-4,112 (-10.90%)0.07%$0 MNov 16, 2026
33XTX Topco Ltd30,246New0.06%$0 MNov 16, 2026
34Morgan Stanley30,105+17,662 (+141.94%)0.06%$0 MNov 13, 2026
35Deutsche Bank AG\29,698-3,579 (-10.76%)0.06%$0 MNov 6, 2026
36Price T Rowe Associates Inc /MD/27,9210 (0.00%)0.06%$0 MNov 16, 2026
37Two Sigma Investments, LP25,6750 (0.00%)0.05%$0 MNov 16, 2026
38Citadel Advisors LLC23,385New0.05%$0 MNov 16, 2026
39New York State Common Retirement Fund19,8000 (0.00%)0.04%$0 MNov 17, 2026
40Quadrature Capital Ltd18,872New0.04%$0 MNov 13, 2026
41Jpmorgan Chase & Co17,136+3,021 (+21.40%)0.03%$0 MNov 12, 2026
42MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.16,504+826 (+5.27%)0.03%$0 MNov 16, 2026
43Vanguard Global Advisers, LLC15,491+156 (+1.02%)0.03%$0 MNov 13, 2026
44Barclays PLC14,519+7,693 (+112.70%)0.03%$0 MNov 6, 2026
45Police & Firemen's Retirement System of New Jersey10,3460 (0.00%)0.02%$0 MNov 9, 2026
46Wells Fargo & Company/mn9,763-20,506 (-67.75%)0.02%$0 MNov 16, 2026
47BNP Paribas Financial Markets8,685+792 (+10.03%)0.02%$0 MNov 12, 2026
48Citigroup Inc6,328-9,645 (-60.38%)0.01%$0 MNov 4, 2026
49Tower Research Capital LLC (TRC)5,183+1,506 (+40.96%)0.01%$0 MNov 16, 2026
50Royal Bank Of Canada4,583+3,347 (+270.79%)0.01%$0 MNov 16, 2026
51Legal & General Group Plc3,3200 (0.00%)0.01%$0 MNov 16, 2026
52Ameritas Investment Partners, Inc.3,0900 (0.00%)0.01%$0 MNov 13, 2026
53Russell Investments Group, Ltd.3,055+333 (+12.23%)0.01%$0 MNov 6, 2026
54FMR LLC1,911+1,674 (+706.33%)0.00%$0 MNov 10, 2026
55Sterling Capital Management LLC988+692 (+233.78%)0.00%$0 MOct 22, 2026
56UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC629New0.00%$0 MNov 16, 2026
57Larson Financial Group LLC300-100 (-25.00%)0.00%$0 MNov 5, 2026
58GAMMA Investing LLC290New0.00%$0 MOct 8, 2026
59SBI Securities Co., Ltd.2510 (0.00%)0.00%$0 MOct 22, 2026
60Global Retirement Partners, LLC170New0.00%$0 MNov 10, 2026
61Northwestern Mutual Wealth Management Co1000 (0.00%)0.00%$0 MNov 13, 2026
62Arax Advisory Partners74New0.00%$0 MNov 12, 2026
63Allworth Financial LP33New0.00%$0 MNov 17, 2026
64Caitong International Asset Management Co., Ltd70 (0.00%)0.00%$0 MOct 29, 2026
65Rockefeller Capital Management L.P.2New0.00%$0 MNov 13, 2026

Mutual funds holding Minerva Neurosciences, Inc.#

51 funds hold shares worth $42 M (about 18.3% of the company). Since their previous reports 44 added shares and 0 sold, buying $11 M net.
Mutual funds holding Minerva Neurosciences, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Federated Hermes Kaufmann FundFederated Advisory Services Company2.59 M$10 M5.2%0.21%no changeJul 31, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.32 M$7 M2.6%<0.01%no changeJun 30, 2026
🇺🇸 Federated Hermes Kaufmann Small Cap FundFederated Advisory Services Company1.71 M$7 M3.4%0.24%no changeJul 31, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors651,463$4 M1.3%<0.01%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.511,673$3 M1.0%<0.01%+5.5%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC370,368$1 M0.74%<0.01%newJul 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors220,170$1 M0.44%<0.01%newJun 30, 2026
🇺🇸 Federated Hermes Kaufmann Small Cap FundFederated Advisory Services Company269,435$1 M0.54%0.04%no changeJul 31, 2026
🇺🇸 Federated Hermes Kaufmann FundFederated Advisory Services Company225,722$1 M0.45%0.02%no changeJul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC152,543$1 M0.31%<0.01%+784%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors113,626$1 M0.23%0.04%newJun 30, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors92,757$1 M0.19%<0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC81,021$0 M0.16%<0.01%+308%May 31, 2026
🇺🇸 Federated Hermes Kaufmann Fund IIFederated Advisory Services Company70,524$0 M0.14%0.35%—Jun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC63,647$0 M0.13%<0.01%newJun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.82,625$0 M0.17%<0.01%newJul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC65,680$0 M0.13%<0.01%+875%May 31, 2026
🇺🇸 Federated Hermes Kaufmann FundFederated Advisory Services Company75,000$0 M0.15%<0.01%no changeJul 31, 2026
🇺🇸 Federated Hermes Kaufmann Small Cap FundFederated Advisory Services Company70,950$0 M0.14%<0.01%no changeJul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC34,308$0 M0.07%<0.01%newJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC45,478$0 M0.09%<0.01%newJul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation26,100$0 M0.05%<0.01%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC27,931$0 M0.06%<0.01%+209%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.23,025$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC22,245$0 M0.04%<0.01%newJun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.31,000$0 M0.06%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.18,555$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.17,542$0 M0.04%<0.01%newJun 30, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC14,657$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.14,200$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC16,244$0 M0.03%<0.01%newJul 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC9,204$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC7,573$0 M0.02%0.02%newJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC7,268$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS7,199$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC9,207$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.5,318$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.5,133$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Federated Hermes Kaufmann Fund IIFederated Advisory Services Company4,769$0 M<0.01%0.02%—Jun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC4,403$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC4,395$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Federated Hermes Kaufmann Fund IIFederated Advisory Services Company4,050$0 M<0.01%0.02%—Jun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC3,445$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management3,090$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.4,206$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC3,987$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC2,722$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC2,633$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC2,098$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS2,866$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC1,640$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC1,390$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC1,390$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC1,793$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC1,255$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.859$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC800$0 M<0.01%<0.01%newJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 57 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Minerva Neurosciences, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
23
since
Minerva Neurosciences, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Remy LuthringerCEO, DirectorSell-3,641$3.760$14 K68,994Form 4
filed Geoff RacePresidentSell-22,082$3.850$85 K51,324Form 4
filed Remy LuthringerCEO, DirectorSell-23,753$3.850$91 K72,635Form 4
filed Frederick W. AhlholmSVP, CFO and SecretarySell-3,580$4.480$16 K17,518Form 4
filed Geoff RacePresidentGrant or award+46,987——73,406Form 4
filed Remy LuthringerCEO, DirectorGrant or award+88,077——96,388Form 4
filed Frederick W. AhlholmSVP, CFO and SecretaryGrant or award+19,843——21,098Form 4
filed David KupferDirectorSell-55,635$0.880$49 K163,553Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Minerva Neurosciences, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.9 M
4.4% of shares · 10.46 days to cover
Buybacks, Q4 2017
$0M
Q4 2017
Shares sold short, last 24 reportsAll stocks →

Stock splits: 3.5-for-1 split

Minerva Neurosciences, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2017Q4 2017$0M

Trading halts

  • 2025-11-17 15:13 UTC, code LUDP, resumed 15:18 UTC

Fails to deliver

  • : 1,768 shares at $3.35
  • : 1,735 shares at $3.81
  • : 654 shares at $3.69
  • : 10,663 shares at $3.49
  • : 4,095 shares at $3.83

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Minerva Neurosciences, Inc. scorecard#

Passes 1 of the 11 checks that could be worked out. Fiscal year 2025; market cap of Sep 30, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-14.8%Free cash flow is -14.8% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-34.67 vs 0.19Diluted EPS -34.67 in fiscal 2025 against 0.19 the year before (report's currency).
    • ✗Net income higher than five years earlier-$293 M-$293 M in fiscal 2025 against $2 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$293 MNet income -$293 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities36.3×Current ratio 36.29 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year11.8%Diluted shares up 11.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Minerva Neurosciences, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Minerva Neurosciences, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue—000041000—
Research and development5.8121315322258353020
General and administrative9.39.9101113171817119.8
Operating expenses15222325453976524130
Operating income−15−22−23−25−451.8−76−52−41−30
Interest and finance income0.91.31.40.60.00.21.51.70.90.2
Income before tax———−32−521.9−74−50−41−31
Income tax————−1.8—−2.30−9.4r0
Net income including minority interests−2931.4−30−32−501.9−72−50−32—
Net income attributable to shareholders−2931.4−30−32−501.9−72−50−32−31
Earnings per share, basic-34.670.19-4.61-6.01-9.35r0.05-1.85-1.29-0.83-0.99
Earnings per share, diluted-34.670.19-4.61-6.01-9.35r0.05-1.85-1.29-0.83-0.99
Shares, weighted average (basic)8.57.66.55.35.3r4139———
Shares, weighted average (diluted)8.57.66.55.35.3r4139393832
Balance sheet
Cash and cash equivalents82214136612521502683
Short-term investments——————2438102—
Current assets832242406227479013084
Property, plant and equipment00.00.00.0——0.00.00.10.0
Right-of-use (leased) assets—————0.10.3———
Goodwill15151515151515151515
Other intangible assets—————1515343434
Total assets98375755775877139184133
Accounts payable0.61.61.81.01.91.02.31.81.41.5
Current liabilities2.32.83.31.42.83.26.63.66.89.7
Lease liabilities (non-current)——————0.1———
Total liabilities234638575695.050495227
Retained earnings−689−395−397−367−335−285−287−215−164−133
Shareholders' equity−141−26−28−208.0532890132106
Total liabilities and equity98375755775877139184133
Shares outstanding437.07.05.35.3r4339393935
Cash-flow statement
Depreciation and amortization0.00.00.0——0.00.00.00.00.0
Share-based compensation1.31.32.04.15.29.79.28.25.03.6
Cash from operating activities−14−20−15−25−25−34−43−423.1−26
Capital expenditure———−0.0————−0.1—
Cash from investing activities000−0.0—251469−10718
Shares bought back————————−0.0—
Cash from financing activities74—20−0.060130.5−3.34777
Change in cash61−204.8−25353.9−2924−57—
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Minerva Neurosciences, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$9.4 M
Dr. Remy Luthringer
Other top executives, average
$4.4 M
the CEO earned 2.1× this
$100 invested is now
$253
Minerva Neurosciences, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dr. Remy Luthringer$9.4 M$9.9 M$4.4 M$253
2024Dr. Remy Luthringer$1.2 M$1.3 M$837 K$140
2023Dr. Remy Luthringer$1.8 M$2.1 M$1.2 M$387

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Minerva Neurosciences, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Directors and officers 5 · Material agreement 2 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 4

Minerva Neurosciences, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Results announced8-K
Shareholder rights changedBylaws or fiscal year changedShareholder vote8-K
Material agreement8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officersShareholder vote8-K
Directors and officers8-K
Material agreementUnregistered share saleBylaws or fiscal year changed8-K
Shareholder vote8-K
Delisting notice8-K
Directors and officers8-K
Delisting notice8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 6, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Minerva Neurosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2016$1 MPrivate placement after listingUnder $2 million1equitySEC
Mar 2015$31 MPrivate placement after listing$10 to $50 million22equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Minerva Neurosciences, Inc. compares in Biotechnology

  • Market cap$167 M · higher than 42% of 726
  • FCF yield-14.8% · higher than 50% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Minerva Neurosciences, Inc.🇺🇸$167 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Sep 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Minerva Neurosciences, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Minerva Neurosciences, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Minerva Neurosciences, Inc.? Suggest a correction